Reports of brain damage call a halt to Bellicum trials: industry news round-up

Pharmaceutical policy announcements, promising drug trial data and more: check out our round-up of the biggest news from the neuroscience and neurology industry this week. Our pick of the headlines this week: Bellicum Pharmaceuticals forced to halt drug trials after three cases of brain damage reported Positive results from Phase III eslicarbazepine acetate epilepsy trial Pfizer confirms cull of neuroscience programs Sunovion announce Phase III Parkinson’s trial results for apomorphine Sage Therapeutics present findings from latest investigation into insomnia drug Bellicum Pharmaceuticals forced to halt drug trials after three cases of brain damage reported The US FDA has imposed a...